LOBBYIST

Kelly Goldberg

← Back to lobbyists

18ACTIVITIES

1ORGS REPRESENTED

52BILLS

Organizations represented

Orgs whose LD-2 filings list Kelly as an active lobbyist, sorted by activity volume.

Pharmaceutical Research and Manufacturers of America (PhRMA)18 activities

Bills they file on

S. 65214 mentions

S. 83214 mentions

S. 89114 mentions

S. 93214 mentions

H.R. 94614 mentions

H.R. 126214 mentions

H.R. 149214 mentions

H.R. 221414 mentions

S. 35513 mentions

S. 141413 mentions

S. 195413 mentions

S. 86412 mentions

S. 229612 mentions

S. 265812 mentions

H.R. 431712 mentions

+ 37 more bills referenced in their activities

Topics in Filings

Policy topics Kelly files on across all their LD-2 activities.

Supply chain policy×15

One Big Beautiful Bill Act×15

Modernizing and Ensuring PBM Accountability×14

Accountability, and Integrity Now and for the Future×14

Vaccine policy×14

Inflation Reduction Act×14

Pharmacy Benefit Manager reform×14

Drug cost and pricing policy×14

Drug importation policy×14

FDA policy×14

Orphan Drug Act×14

Compounding policy×14

Show all 76 topics (+64 more) ▾

Clinical trial policy×14

Issues 340B drug discount program policy×14

Biosimilar approval and reimbursement policy×14

Artificial intelligence policy×14

FDA Modernization×14

Biosimilar Red Tape Elimination Act×13

Bipartisan Health Care Act×12

BIOSECURE Act×12

IRA price negotiation expansion policy×12

Most Favored Nation×12

MAHA Commission Report×12

Make Our Children Healthy Again Competition policy×12

Issues 340B rebate pilot program Patient assistance program policy×12

Biosimilars Access and Affordability Act×12

PBM Price Transparency and Accountability Act×11

Mikaela Naylon Give Kids a Chance Act×11

PBM Reform×11

HELP Copays Act×11

Antimicrobial resistance policy×11

CLEAR LABELS Act×10

Most Favored Patients Act×10

FAIR ACT×10

SECURE Rx Act×10

User fee issues×4

Rural Development×4

Give Kids a Chance Act×3

Antimicrobial resistance×3

Science, and Related Agencies Appropriations Act, 2026×3

Accelerated approval policy×2

Competition policy×2

Patient assistance program policy×2

Drug shortages policy×2

Food and Drug Administration, and Related Agencies Appropriations Act, 2026 H×2

Res. 566: Providing for consideration of the Senate amendment to the bill×2

RESTORE Patent Rights Act×2

Protecting Patients from Deceptive Drug Ads Act×1

Innovation in Pediatric Drugs Act×1

Pandemic preparedness policy×1

Tariff policy×1

Biopharmaceutical innovation policy×1

International intellectual property and market access policy×1

Pricing and reimbursement policy×1

WTO TRIPS waiver policy×1

China outbound investment policy×1

Military Construction×1

Skinny Labels×1

Big Savings Act×1

Affordable Prescriptions for Patients Act×1

Stop STALLING Act×1

Preserve Access to Affordable Generics and Biosimilars Act×1

Interagency Patent Coordination and Improvement Act×1

Bayh-Dole march-in rights policy×1

Patent thicket policy×1

Patent use codes policy×1

AI patent policy×1

Patent eligibility policy×1

Post-grant proceeding policy×1

Patent submission policy×1

Expedited Acccess to Biosimilars Act×1

MAPS Act×1

Medication Affordability and Patent Integrity Act×1

Orphan Cures Act×1

Prescription Information Modernization×1

Open Payments Expansion Act×1

Issue mix

LDA general-issue codes weighted by activity count.

Health Issues14

Budget/Appropriations2

Trade (domestic/foreign)1